Return To Phacilitate
  • When 7-9 September, 2026
  • Where InterContinental Barcelona
  • Search
Sponsorship Opportunities Apply to attend
SEARCH

CDMOs

Where Europe's biotechs come to find their manufacturing partners

Advanced Therapies Europe brings together the biotech and pharma teams making partner decisions about their next stage of manufacturing, scale-up and supply.

Whether you're supporting clinical-stage programmes, building viral vector capacity, or competing for late-stage manufacturing contracts, ATE puts you in front of the people choosing where their therapies get made.

If you're scaling into Europe, or expanding your footprint within it — ATE puts you in a curated room of buyers, not browsers. Every conversation is with someone actively making decisions about tools, technology, and infrastructure.

✅ 996 pre-arranged meetings in 2025.
✅ 600 senior decision-makers across the European CGT ecosystem.
✅ Curated meeting concierge to match you with the right accounts.

Apply to attend

Manufacturing Europe's Next Wave of Therapies

Europe's CGT manufacturing landscape is changing fast. Approval volumes are climbing, modalities are diversifying, and biotech clients expect more from their CDMO partners than ever before. They want speed, cost discipline, regulatory consistency, and the ability to scale without losing quality.

The CDMOs who win in Europe over the next five years will be the ones already in the right rooms, having the right conversations, with the biotech and pharma leaders making outsourcing decisions now.

  • Biotech clients are looking for partners who can scale viral vector and cell therapy supply reliably, not just at lab scale
  • Cost of goods, automation and closed systems are now central to outsourcing decisions, not bonus features
  • Regulatory alignment across jurisdictions is a growing pressure, and clients want CDMOs who can navigate it with them

This is where ATE becomes commercially critical: 

Meet the biotechs choosing where to manufacture

Connect with clinical-stage and scaling biotech teams actively reviewing their manufacturing strategy, in a curated room of senior decision-makers.

Stay close to where the industry is heading

Hear directly from biotech and pharma leaders on viral vector supply, automation, decentralised manufacturing and where outsourcing demand is shifting in Europe.

Position against Europe's regulatory reality

Understand the regulatory and access pressures your clients are working through, so your offer fits the realities of bringing therapies to market across European jurisdictions.

Use your time on the conversations that matter

996 pre-arranged, concierge-led meetings ensure your time is spent on real opportunities, not chasing leads.

Key Agenda Themes in 2026

  • AAV manufacturing at scale - Spotlight sessions and fireside chats covering what broke at scale, how next-generation AAV manufacturing is tackling yield, consistency and toxicity risk, and what teams would design differently today.
     

  • CMC cost of goods -  A dedicated panel and spotlight sessions on engineering cost out of CMC, where process and platform choices change the economics, and how to fix the numbers before scale makes them worse.
     

  • Industrialising cell and gene therapy - Sessions on what it really takes to build for the long game, why scaling production is no longer the hard part, and what now determines commercial success.

  • Automation and decentralised manufacturing - Dedicated Special Interest Groups bringing the industry together on the operational shifts shaping how cell and gene therapies will be produced.
     

  • Europe's ATMP rulebook reset - A plenary on the 12-month pathway from fragmented rules to trusted EU execution, the regulatory shift your clients are working through right now.


    View the Agenda

Built for CDMOs Ready to Compete in Europe

If you’re preparing for your next funding round, strategic partnership, or commercial milestone, this is where those conversations move forward. Designed for clinical-stage and scaling biotechs, Advanced Therapies Europe gives you direct access to the capital, partners, and insight needed to move from progress to execution.

If you’re evaluating where to spend your time and budget this year, this gives you a clear view of the return.

The Delegate Pack shows you who’s in the room, what conversations are happening, and how to make your time count, before you decide to attend.

Inside the delegate pack:

  • A breakdown of attending biotechs, pharma, CDMOs and investors
  • Insight into the partnerships and conversations happening across the room
  • How the 1:1 meeting concierge works and how you’re matched
  • An overview of the agenda, themes, and key discussion area
     

Download the Delegate Pack

Who you'll meet at ATE 2026

2025 Attendee List 2025 Exhibitor List

600
CGT Leaders
40+
Countries
100000000
EUR Capital Represented
1000+
1:1 Partner Meetings

 

  • "What an incredible few days at the ATE conference by Phacilitate! Grateful for the power of my network and the opportunity to meet so many familiar faces while growing it further.”
    Head of Business Development: Cell Therapy and Laboratory Services | Cell and Gene Therapy
  • “Impactful moments and connections.”
    Director Global Cell and Gene Therapies Portfolio Management | EMBA | Deep Tech
  • “Already having fantastic conversations here at ATE24 in Lisbon.”
    Experienced Leader in Cell and Gene Therapy Business and Commercial Strategy
Search